Literature DB >> 7727647

Relapse of tularemia after aminoglycoside therapy: case report and discussion of therapeutic options.

G F Risi1, D J Pombo.   

Abstract

We describe a patient with ulceroglandular tularemia who initially responded to therapy with gentamicin but then clinically relapsed. Ciprofloxacin was subsequently given for 28 days, and the patient was clinically cured. Aminoglycosides have been considered the drugs of choice in the treatment of tularemia; however, potential alternative treatments do exist. We review the English-language literature on this topic.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7727647     DOI： 10.1093/clinids/20.1.174

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  14 in total

Review 1.  Use of aminoglycosides in treatment of infections due to intracellular bacteria.

Authors:  M Maurin; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

2.  Broth microdilution susceptibility testing of Francisella tularensis: quality control limits for nine antimicrobial agents and three standard quality control strains.

Authors:  Steven D Brown; Karen Krisher; Maria M Traczewski
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

3.  Francisella tularensis: a red-blooded pathogen.

Authors:  J Wayne Conlan
Journal:  J Infect Dis       Date:  2011-07-01       Impact factor: 5.226

4.  A case of tularemia after an endurance run in a non-endemic region.

Authors:  R Meckenstock; A Therby; A Le Monnier; D Khau; S Monnier; B Pangon; A Greder-Belan
Journal:  Infection       Date:  2012-10-17       Impact factor: 3.553

5.  Bactericidal activities of antibiotics against intracellular Francisella tularensis.

Authors:  M Maurin; N F Mersali; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

6.  Post-exposure immunization against Francisella tularensis membrane proteins augments protective efficacy of gentamicin in a mouse model of pneumonic tularemia.

Authors:  Marjorie D Sutherland; Andrew W Goodyear; Ryan M Troyer; Jeffrey C Chandler; Steven W Dow; John T Belisle
Journal:  Vaccine       Date:  2012-05-28       Impact factor: 3.641

7.  Effective, broad spectrum control of virulent bacterial infections using cationic DNA liposome complexes combined with bacterial antigens.

Authors:  Robin Ireland; Norma Olivares-Zavaleta; Jonathan M Warawa; Frank C Gherardini; Clayton Jarrett; B Joseph Hinnebusch; John T Belisle; Jeffery Fairman; Catharine M Bosio
Journal:  PLoS Pathog       Date:  2010-05-27       Impact factor: 6.823

8.  B1a cells enhance susceptibility to infection with virulent Francisella tularensis via modulation of NK/NKT cell responses.

Authors:  Deborah D Crane; Amanda J Griffin; Tara D Wehrly; Catharine M Bosio
Journal:  J Immunol       Date:  2013-02-01       Impact factor: 5.422

9.  Francisella tularensis SchuS4 and SchuS4 lipids inhibit IL-12p40 in primary human dendritic cells by inhibition of IRF1 and IRF8.

Authors:  Robin Ireland; Rong Wang; Joshua B Alinger; Pamela Small; Catharine M Bosio
Journal:  J Immunol       Date:  2013-07-01       Impact factor: 5.422

Review 10.  Tularemia.

Authors:  Jill Ellis; Petra C F Oyston; Michael Green; Richard W Titball
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.